C4 Therapeutics reported a narrowed net loss for the second quarter 2026, driven by lower personnel-related stock-based compensation and a slight increase in collaboration revenue. The company successfully strengthened its balance sheet through strategic financing and a new partnership payment, providing a projected cash runway through the end of 2028.
Key Highlights
- Cash and marketable securities increased to $300.4 million, bolstered by $33.5 million in net proceeds from an ATM program and a $20.0 million upfront payment from Roche.
- Phase 1 clinical data for cemsidomide demonstrated deep responses in heavily pretreated patients, showing a 53% overall response rate at the 100 µg dose level.
- Total operating expenses decreased to $33.1 million from $35.0 million year-over-year, primarily due to reduced research and development personnel costs.